◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Apogee Therapeutics, Inc. Common Stock (APGE) Net Income 2022–TTM

Name: Apogee Therapeutics, Inc. Common Stock (APGE) net income history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Apogee Therapeutics, Inc. Common Stock annual net income for fiscal TTM was -$275 million, a decrease of 7.4% from -$256 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

APGE Annual Net Income

Net Income (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Net Income	($275M)	($256M)	($182M)	($84M)	($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

APGE Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Net Income	($86M)	($74M)	($69M)	($65M)	($66M)	($55M)	($67M)	($49M)	($34M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

BMRN Net Income — Biomarin Pharmaceutical Inc
MDGL Net Income — Madrigal Pharmaceuticals Inc
CORT Net Income — Corcept Therapeutics Incorporated
AXSM Net Income — Axsome Therapeutics Inc
KRYS Net Income — Krystal Biotech Inc
KYMR Net Income — Kymera Therapeutics Inc

More APGE metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All APGE financial statements → Interactive APGE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.